Ocuphire Pharma Inc (R3X1.BE)
| Previous close | 1.5540 |
| Open | 1.5640 |
| Bid | 1.4780 x N/A |
| Ask | 1.6160 x N/A |
| Day's range | 1.5500 - 1.5760 |
| 52-week range | 1.4040 - 4.0650 |
| Volume | |
| Avg. volume | 16 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 09 Aug 2024 - 13 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireOcuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June
FARMINGTON HILLS, Mich., June 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced that clinical updates on the Company’s lead candidate APX3330 for diabetic retinopathy (DR) will be featured in upcoming presentations at the Clinical Trials at the Summit meeting on June 8 in Park City, Utah, a
Simply Wall St.Ocuphire Pharma First Quarter 2024 Earnings: Misses Expectations
Ocuphire Pharma ( NASDAQ:OCUP ) First Quarter 2024 Results Key Financial Results Revenue: US$1.71m (down 2.2% from 1Q...
- GlobeNewswire
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced financial results for the first quarter ended March 31, 2024, and provided a corporate update. “Ocuphire has made significant progress in 2024, with important developments for both APX3330 and RYZUMVI™,” said Georg
